Akonni Wins $435K SBIR Grant to Develop POC Tuberculosis Dx on PCR Array Technology

In addition, Akonni is developing tests based on the biochip technology for a number of other infectious agents, and is designing and testing an integrated instrument platform to perform the tests, with the ultimate goal of seeking US regulatory clearance.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.